{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5f61e5b80af9f547701a9bd7/637b8ee291bde60010904dfc?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"What would be the impact of a TRIPS waiver extension?","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/5f61e5b80af9f547701a9bd7/1650363770474-8977d1aca5e2d6b27df94125671ed292.jpeg?height=200","description":"<p>Welcome to Health Conversation. Today we're asking Peter Guenter, CEO of Healthcare at Merck, <em>'What would be the impact of a TRIPS waiver extension?'</em>. Listen to hear their discussion on the challenge and how we're preparing for the future.</p>","author_name":"EFPIA"}